Abdulrahman Katib on RENOVE’s Support of Practice in VTE Longterm Managment
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
”RENOVE is an important RCT that supported our practice in VTE longterm managment.
It was a high-quality multicenter randomized clinical trial that provided strong real-world evidence on extended anticoagulation after VTE.
It showed that long-term dosing decisions should focus not only on preventing recurrence, but also on reducing bleeding risk, which directly improved how we individualize therapy in practice.
Since RENOVE, our approach became more patient-centered, with more confident use of reduced-dose DOAC strategies in selected patients needing extended anticoagulation.”
Read the full article here.
Article: Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial
Authors: Francis Couturaud et al. for the RENOVE Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian